Roux-en-Y Gastric Bypass
Abbreviation: RYGB
Definition
A bariatric surgical procedure that creates a small stomach pouch and connects it directly to a more distal segment of the small intestine, bypassing the rest of the stomach and the upper small intestine. Produces 25-35% total body weight loss on average at 1-2 years.
Roux-en-Y Gastric Bypass (RYGB)
Roux-en-Y gastric bypass is the historical reference standard of bariatric surgery, producing the largest and most durable weight loss of the common bariatric procedures. Performed laparoscopically in most modern practice, the surgeon creates a small (~30 mL) stomach pouch and connects it via a “Roux limb” of small intestine to a more distal segment, bypassing the rest of the stomach and the duodenum and most of the jejunum.
The mechanism of weight loss combines several effects: restriction (the small pouch holds little food), altered nutrient absorption (food bypasses the upper small intestine where much absorption normally occurs), and hormonal changes (substantial post-operative changes in GLP-1, PYY, ghrelin, bile acids, and gut microbiota). The hormonal effects, including dramatically elevated post-meal GLP-1 secretion, drive much of the durable appetite suppression seen after RYGB.
Average outcomes at 1-2 years: 25-35% total body weight loss, type 2 diabetes remission in approximately 60-80% of patients (often within days of surgery, before significant weight loss has occurred), substantial improvement in lipids, blood pressure, and obstructive sleep apnea, and durable cardiovascular risk reduction. Long-term outcomes show somewhat more weight regain than the initial nadir but maintained weight loss in the 20-25% range at 10 years. Complications can include nutritional deficiencies (iron, B12, calcium, vitamin D), dumping syndrome, marginal ulcer, and internal hernia.
In modern obesity pharmacology, the weight-loss range historically achievable only with RYGB is now being approached by triple-agonist therapy. Retatrutide TRIUMPH-1 reported a 104-week extension result of -30.3% mean weight loss in the BMI ≥35 subgroup, overlapping with average RYGB outcomes. This represents a meaningful shift in how patients and clinicians weigh surgical versus pharmacological options for severe obesity.